(Q50453658)

14 March 2018

title

Proposal of Japan Red Cross score for sorafenib therapy in hepatocellular carcinoma. (English)

1 reference

14 March 2018

10

Namiki Izumi

1 reference

14 March 2018

author name string

Haruhiko Takeda

1

1 reference

14 March 2018

Hiroki Nishikawa

2

1 reference

14 March 2018

Yukio Osaki

3

1 reference

14 March 2018

Kaoru Tsuchiya

4

1 reference

14 March 2018

Kouji Joko

5

1 reference

14 March 2018

Chikara Ogawa

6

1 reference

14 March 2018

Hiroyoshi Taniguchi

7

1 reference

14 March 2018

Etsuro Orito

8

1 reference

14 March 2018

Yasushi Uchida

9

1 reference

14 March 2018

Japanese Red Cross Liver Study Group

11

1 reference

14 March 2018

publication date

11 January 2015

1 reference

14 March 2018

published in

Hepatology Research

1 reference

14 March 2018

volume

45

1 reference

14 March 2018

issue

10

1 reference

14 March 2018

page(s)

E130-40

1 reference

14 March 2018

cites work

Hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12480

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12480

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12480

Sorafenib: from literature to clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12480

Optimized management of advanced hepatocellular carcinoma: four long-lasting responses to sorafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12480

Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12480

Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12480

Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective comparison with previously known prognostic models.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12480

Predictors of survival in patients with established cirrhosis and hepatocellular carcinoma treated with sorafenib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12480

Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12480

Toxicity and response criteria of the Eastern Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12480

EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12480

Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12480

In a 'real-world', clinic-based community setting, sorafenib dose of 400 mg/day is as effective as standard dose of 800 mg/day in patients with advanced hepatocellular carcimona, with better tolerance and similar survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12480

Modified RECIST (mRECIST) assessment for hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12480

Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12480

Characteristics of 18 patients with hepatocellular carcinoma who obtained a complete response after treatment with sorafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12480

GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib): second interim analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12480

Multidisciplinary management of hepatocellular carcinoma in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12480

Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12480

Comparison of systems for assessment of post-therapeutic response to sorafenib for hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12480

FGF3/FGF4 amplification and multiple lung metastases in responders to sorafenib in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12480

Identification of prognostic biomarkers in hepatitis B virus-related hepatocellular carcinoma and stratification by integrative multi-omics analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12480

Next generation sequencing reveals genetic landscape of hepatocellular carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12480

Relationship between baseline hepatic status and outcome, and effect of sorafenib on liver function: SHARP trial subanalyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12480

Validation of a new prognostic staging system for hepatocellular carcinoma: The JIS score compared with the CLIP score

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12480

21 January 2018

Identifiers

DOI

10.1111/HEPR.12480

1 reference

14 March 2018

PubMed ID

25581351

1 reference

14 March 2018